Brought to you by 
Chiesi grants Curosurf license, invests in Cornerstone
03 Jun 2021
Executive Summary
Italy's Chiesi Farmaceutici SPA has granted spec pharma Cornerstone Therapeutics an exclusive US license to sell its porcine-derived lung surfactant Curosurf (poractant alfa) for the next ten years (renewable thereafter automatically in one-year increments). Cornerstone also obtained the first right of offer on any drugs or technologies--most likely in the respiratory field, including Phase I synthetic surfactant Nymusa for sleep apnea--which Chiesi plans to launch in the US.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiesi grants Curosurf license, invests in Cornerstone
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice